Table 2.
Summary of the clinicopathological features of the five selected articles. Legend: Ref., reference; N., number; HR, hazard ratio; ER, estrogen receptor; PR, progesterone receptor; DCIS, ductal carcinoma in situ; DFS, disease-free survival.
| Author | Year | Ref. | Country | N. of Cases | Period | Prognostic Factors Examined | HR Calculated on | Type of Analysis |
|---|---|---|---|---|---|---|---|---|
| Fang | 2016 | [29] | China | 84 | 2002–2014 | N. of foci, ER, PR, HER2 | DFS | Multivariate |
| Hacking | 2022 | [30] | USA | 72 | 2010–2020 | DCIS size, N. of foci, nuclear grade, age, ER, PR, HER2, SLNB, surgery, radiation status | DFS | Univariate 1 |
| Li | 2021 | [12] | China | 1286 | 2008–2019 | Surgery, tumor volume, grade, Ki67, age, lymph node status, margin, chemotherapy, radiotherapy | DFS | Univariate (also multivariate for some of them) |
| Pu | 2018 | [31] | China | 242 | 1997–2014 | Age, tumor size, lymph node status, grade, necrosis, ER, PR, HER2, Ki67, chemotherapy, radiotherapy, endocrine therapy, trastuzumab, therapeutic schemes | DFS | Univariate (also multivariate for some of them) |
| Rakovitch | 2019 | [32] | Canada | 267 | 1994–2003 | N. of foci of microinvasion | DFS | Multivariate |
1 Multivariate values were also available, but their confidence intervals were so high that it was necessary to consider univariate values.